In addition, side effects associated with the mTOR inhibitor rapamycin for DKD, such as hyperglycaemia, insulin resistance and dyslipidaemia, have also been reported, which may be related to the metabolic profile of the pancreas and other insulin-resistant tissues, including the liver and muscle (Viana et al., 2018). This evidence concerns the gene MTOR and diabetic kidney disease.